KINTOR PHARMA-B (09939) announced its interim results for 2025, showing revenue increased from zero in the same period last year to RMB 6 million. The company recorded a net loss of RMB 83.268 million, representing a 16.47% increase year-on-year, with loss per share of RMB 0.19.

According to the announcement, the revenue increase was primarily attributed to global sales of the company's new high-end cosmetics brand KOSHINÉ. The group will continue to explore different approaches to further advance the global commercialization of its cosmetics products.

The increased loss was mainly due to higher research and development costs and marketing expenses incurred by the group.